Profile data is unavailable for this security.
About the company
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.
- Revenue in USD (TTM)16.05m
- Net income in USD-196.83m
- Incorporated2018
- Employees255.00
- LocationVerve Therapeutics Inc201 Brookline Avenue, Suite 601BOSTON 02215United StatesUSA
- Phone+1 (978) 501-3026
- Fax+1 (302) 655-5049
- Websitehttps://www.vervetx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IGM Biosciences Inc | 2.11m | -236.92m | 429.69m | 216.00 | -- | 2.66 | -- | 204.13 | -4.31 | -4.31 | 0.0375 | 2.74 | 0.005 | -- | -- | 9,397.32 | -56.49 | -44.66 | -62.57 | -48.20 | -- | -- | -11,255.25 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Altimmune Inc | 410.00k | -92.77m | 433.21m | 59.00 | -- | 2.50 | -- | 1,056.62 | -1.59 | -1.59 | 0.007 | 2.44 | 0.0022 | -- | 1.47 | 6,949.15 | -49.42 | -39.62 | -53.14 | -42.58 | -- | -- | -22,626.10 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Tourmaline Bio Inc | 0.00 | -32.94m | 434.96m | 44.00 | -- | 1.23 | -- | -- | -5.35 | -5.35 | 0.00 | 13.81 | 0.00 | -- | -- | 0.00 | -12.39 | -- | -12.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Exscientia PLC (ADR) | 24.87m | -164.01m | 436.19m | 483.00 | -- | 1.52 | -- | 17.54 | -1.30 | -1.30 | 0.1968 | 3.32 | 0.0364 | -- | 34.98 | 51,484.14 | -24.02 | -- | -27.31 | -- | -34.40 | -- | -659.56 | -- | -- | -- | 0.0556 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| Tscan Therapeutics Inc | 14.81m | -96.80m | 444.05m | 161.00 | -- | 3.27 | -- | 29.98 | -1.28 | -1.28 | 0.1784 | 2.57 | 0.0715 | -- | -- | 96,181.82 | -46.72 | -- | -52.48 | -- | -- | -- | -653.50 | -- | -- | -- | 0.1974 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Avid Bioservices Inc | 136.74m | -18.26m | 449.75m | 365.00 | -- | 2.50 | -- | 3.29 | -0.2888 | -0.2888 | 2.17 | 2.84 | 0.302 | 3.18 | 4.89 | 374,616.40 | -4.03 | 10.70 | -6.13 | 15.18 | 7.47 | 22.72 | -13.35 | 25.86 | 0.3097 | -4.47 | 0.4548 | 0.00 | 24.81 | 22.72 | -99.80 | -- | 82.98 | -- |
| Absci Corp | 5.35m | -109.19m | 450.07m | 155.00 | -- | 1.87 | -- | 84.17 | -1.17 | -1.17 | 0.0569 | 2.12 | 0.0187 | -- | 7.82 | 34,496.77 | -38.26 | -- | -42.14 | -- | -- | -- | -2,042.01 | -- | -- | -107.74 | 0.0298 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Alector Inc | 96.41m | -120.61m | 451.08m | 244.00 | -- | 2.52 | -- | 4.68 | -1.39 | -1.39 | 1.12 | 1.86 | 0.1393 | -- | -- | 395,106.60 | -17.43 | -20.00 | -21.55 | -23.81 | -- | -- | -125.11 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Verve Therapeutics Inc | 16.05m | -196.83m | 455.09m | 255.00 | -- | 0.7792 | -- | 28.36 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -129.44m | 455.42m | 186.00 | -- | 1.76 | -- | -- | -2.37 | -2.37 | 0.00 | 3.79 | 0.00 | -- | -- | 0.00 | -53.68 | -40.85 | -57.32 | -44.48 | -- | -- | -- | -- | -- | -43.34 | 0.1009 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Adaptive Biotechnologies Corp | 174.50m | -215.06m | 461.26m | 709.00 | -- | 1.68 | -- | 2.64 | -1.48 | -1.48 | 1.20 | 1.87 | 0.2472 | 4.52 | 4.78 | 246,124.10 | -30.48 | -19.69 | -34.73 | -22.06 | 57.06 | 67.18 | -123.29 | -122.27 | 4.35 | -- | 0.3238 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Voyager Therapeutics Inc | 119.04m | -3.04m | 462.89m | 162.00 | -- | 1.36 | 304.93 | 3.89 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Fulcrum Therapeutics Inc | 2.51m | -99.43m | 463.04m | 76.00 | -- | 2.17 | -- | 184.48 | -1.61 | -1.61 | 0.0406 | 3.44 | 0.0091 | -- | 2.14 | 33,026.32 | -35.91 | -50.55 | -37.62 | -55.91 | -- | -- | -3,961.20 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Lenz Therapeutics Inc | 0.00 | -117.37m | 473.41m | 6.00 | -- | 2.39 | -- | -- | -15.88 | -15.88 | 0.00 | 7.77 | 0.00 | -- | -- | 0.00 | -44.51 | -- | -47.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
| SIGA Technologies Inc | 157.02m | 79.26m | 474.39m | 45.00 | 6.08 | 2.88 | 5.94 | 3.02 | 1.10 | 1.10 | 2.20 | 2.32 | 0.7354 | 0.3631 | 10.32 | 3,489,424.00 | 37.12 | 22.34 | 47.49 | 27.56 | 87.71 | 88.65 | 50.48 | 41.14 | 2.19 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Cartesian Therapeutics Inc | 25.91m | -254.87m | 485.65m | 38.00 | -- | -- | -- | 18.75 | -48.02 | -48.02 | 4.94 | -21.18 | 0.1077 | -- | 5.86 | 681,736.80 | -106.00 | -43.66 | -122.03 | -66.84 | -- | -- | -983.83 | -136.35 | -- | -0.5249 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
Data as of Jun 14 2024. Currency figures normalised to Verve Therapeutics Inc's reporting currency: US Dollar USD
51.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 6.24m | 7.94% |
| ARK Investment Management LLCas of 31 Mar 2024 | 6.04m | 7.69% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 5.10m | 6.49% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.80m | 6.11% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 4.58m | 5.83% |
| Federated Global Investment Management Corp.as of 31 Mar 2024 | 3.56m | 4.53% |
| Casdin Capital LLCas of 31 Mar 2024 | 3.06m | 3.90% |
| Nikko Asset Management Americas, Inc.as of 31 Mar 2024 | 2.59m | 3.30% |
| Nikko Asset Management Co., Ltd.as of 31 Mar 2024 | 2.59m | 3.30% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.16m | 2.75% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
